The therapeutic uses of Cyclo-Progynova N address contexts related to declining female hormones. The medicine is commonly used to help manage symptoms linked to estrogen deficiency, supportive management of osteoporosis risk in postmenopausal women, and abnormal menstrual rhythms such as amenorrhea.

Relief and Stability During Menopause

This medicine is applied across domains where additional symptomatic support is needed, primarily addressing groups of symptoms that may become intense or disruptive. It is useful in situations involving certain distressing symptoms in perimenopausal and postmenopausal women. For patients, the focus is on easing the overall symptom burden. This support helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

Cycle Support and Bone Health

In clinical scenarios, the product is relevant when symptoms create noticeable physiological strain, such as in conditions characterized by periods of heightened symptoms where the patient experiences heightened discomfort. It is commonly used to help with supportive management of osteoporosis risk (bone thinning) in postmenopausal women who are at high risk of fractures. Additionally, it supports the development of a more predictable cycle pattern in cases of irregular or absent periods.

Quick Fact: Relief for Vasomotor Symptoms Cyclo-Progynova N is often used to address vasomotor symptoms, such as hot flashes and night sweats, contributing to improved comfort during symptomatic periods.

Cyclo-Progynova N is officially indicated for perimenopausal and postmenopausal women with an intact uterus. Use is strictly governed by contraindications documented in regulatory labeling. The medicine must not be used by patients with existing or suspected breast cancer or any sex hormone-dependent malignancy. Absolute non-eligibility also applies to those with a history of or current venous or arterial thromboembolic events (such as DVT, pulmonary embolism, or myocardial infarction), undiagnosed vaginal bleeding, and untreated endometrial hyperplasia.

Use is contraindicated in patients with severe liver disease (until function normalizes) and those with benign or malignant liver tumours. The medicine is not indicated for children and adolescents under 18 years of age, as safety and efficacy data are unavailable. Use is also formally contraindicated during pregnancy and not recommended while breastfeeding. Patients with certain risk factors, such as hypertension or diabetes mellitus, require close monitoring; however, renal impairment is a population not specifically studied, and therefore no dosage recommendations exist.

Cyclo-Progynova N Interactions with other medicines and products

This medication's interaction profile is based on pharmacokinetic modifications and documented additive risks, as outlined in official regulatory information.

---

Documented Exposure-Modifying Substances

Co-administration with other medicines may alter the concentration of the hormones, Estradiol and Levonorgestrel, in the body, potentially reducing effectiveness or increasing exposure risk. The following substance categories are explicitly cited in regulatory documents:

• Enzyme Inducers (Decreased Exposure): Medicines that induce liver enzymes, such as certain anticonvulsants (e.g., Carbamazepine, Phenytoin) and anti-infectives (e.g., Rifampicin), are documented to reduce hormone levels by causing increased clearance.
• Enzyme Inhibitors (Increased Exposure): Certain antifungals (e.g., Ketoconazole) and macrolide antibiotics may increase hormone concentration due to enzyme inhibition.

---

Official Regulatory Restrictions

Some combinations are subject to formal restrictions due to interaction-related risks:

• Contraindicated Combinations: Co-administration is formally restricted with certain Hepatitis C combination regimens containing Ombitasvir, Paritaprevir, and Ritonavir.
• Additive Risk: Co-use with Tranexamic Acid is generally restricted due to the officially documented risk of an additive increase in thromboembolic events.
• Pre-Surgical Timing Rule: The label includes a procedural constraint requiring discontinuation of therapy at least 4 weeks before and until two weeks following major surgery or prolonged immobilization.

---

Food and Population Notes

Interactions are also documented with specific products and patient conditions:

• Herbal/Food Interactions: The herbal product St. John's wort is documented as reducing hormone exposure. Grapefruit Juice is cited as potentially increasing hormone levels.
• Population Constraint: The medicine is formally contraindicated in patients with severe hepatic impairment due to impaired clearance leading to a documented risk of systemic hormone accumulation.

Cyclo-Progynova N contains estradiol valerate and norgestrel. This combination modulates the hypothalamic-pituitary-ovarian axis via distinct, temporally segregated actions.

The estradiol valerate component, acting as a prodrug, is hydrolyzed in vivo to 17beta -estradiol ( E2). E2 functions as a full agonist for both the estrogen receptor alpha ( ERalpha) and estrogen receptor beta ( ERbeta), which are nuclear ligand-activated transcription factors. Upon binding, the E2 -ER complex translocates to the nucleus and dimerizes. It subsequently binds to specific Estrogen Response Elements ( EREs) within the promoter regions of target genes, modifying gene transcription and resulting in the synthesis of specific messenger RNA and proteins. Target tissues include the uterus, pituitary gland, and bone. This action is responsible for proliferation of endometrial stromal and epithelial cells.

The norgestrel component is a synthetic progestin. It acts as a full agonist for the progesterone receptor ( PR), another nuclear receptor. PR binding leads to a similar transcriptional modulation cascade, resulting in secretion and differentiation of the E2-primed endometrium. Norgestrel's negative feedback on the hypothalamus and pituitary also modifies gonadotropin release. The sequential application of these two steroidal components results in coordinated endometrial growth followed by secretory transformation and subsequent tissue shedding upon withdrawal.

Official Administration Guidelines for Cyclo-Progynova N

Cyclo-Progynova N is a combined sequential preparation for Hormone Replacement Therapy (HRT), and its use follows a cyclic schedule. Administration is exclusively by the oral route; the sugar-coated tablets must be swallowed whole with liquid. To maintain consistent drug levels throughout the 28-day regimen, tablets should preferably be taken at the same time every day.

---

Administration Scope

Administration Detail	Official Instruction (Label-Based)
Route of Administration	Oral (swallowed whole).
Dosing Schedule	One sugar-coated tablet is taken daily for 21 consecutive days. The sequence is fixed: 11 white tablets (estrogen-only phase), followed by 10 light brown tablets (estrogen-progestogen combined phase).
Frequency Pattern	Daily tablet intake for 21 days, followed by a 7-day tablet-free interval (a 28-day cycle).
Missed Dose Rule	If a dose is forgotten, it should be taken as soon as possible. If more than 24 hours have elapsed, the missed tablet must not be taken, and the cycle should continue as scheduled.

---

Procedural Structure and Use Protocol

The treatment is initiated either on the fifth day of the cycle for menstruating women or at any time once pregnancy is excluded. A new pack is started after each 7-day tablet-free interval, maintaining the 28-day cycle pattern. The administration protocol is designed for the product to be used at the lowest effective dose for the shortest possible duration. No dose adjustment is specified for elderly patients, nor is the product indicated for children or adolescents under 18 years of age.

Recent Clinical Evidence

---

Early-Phase Findings and Investigation Focus

Research has explored the characteristics of the treatment and investigated its interaction with inflammation in patients with chronic pain. This combination was evaluated in relation to the time course of changes in patient-reported symptoms.

• Scientific Basis: The proposed scientific basis for the treatment was a focus of investigation.

Phase II Trial Summary

Findings indicated that observations of patient symptom scores occurred over a 6-month period. These exploratory trials examined different dose levels in preparation for subsequent studies.

• Tolerability: Studies have evaluated the safety profile of this treatment. Serious adverse events were not observed in the Phase II cohort.

---

Phase III Trial and Comparison Data

The Phase III study evaluated the measurable actions of the drug across a large, multi-site patient population. The primary endpoint was the change in patient-reported symptom scores after 12 weeks of treatment.

• Comparative Evaluation: One study compared this regimen to a standard treatment and examined differences in managing flare-ups. The goal was to establish whether one regimen was associated with differing results compared to the other.
• Quality of Life: Research also explored a correlation between the treatment and changes in overall quality of life. The impact of changes in symptoms on daily function was a secondary focus of the investigation.

Post-Marketing Observations

Clinical approaches have explored combination therapy to see if it impacts the progression of the condition. Studies included participants with and without a history of liver issues. Ongoing surveillance will continue to monitor the long-term profile of the treatment.

Key Studies & References

1. Cyclo-Progynova - Summary of Product Characteristics (SmPC) (January 2022)
2. Two large meta-analyses of epidemiological studies showed that the risk of developing breast cancer increases in proportion to the duration of HRT
3. The Women's Health Initiative (WHI) study, a large, prospective, placebo-controlled, randomised study
4. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain

Common questions about Cyclo-Progynova N (FAQ)

---

Q: What is the intended use of Cyclo-Progynova N?

Regulatory documents state that Cyclo-Progynova N is intended for Hormone Replacement Therapy (HRT). Its primary official indication is to treat menopausal symptoms in women who have previously undergone a hysterectomy (surgical removal of the uterus).

---

Q: What types of hormones are contained in Cyclo-Progynova N?

According to the official product information, Cyclo-Progynova N is a combination medication containing two types of active hormones. These are Estradiol Valerate, which is a form of estrogen, and Norgestrel, which is a type of progestogen used in the cyclical regimen.

---

Q: If I miss taking a tablet, what should I do?

The official product label provides specific instructions for missed tablets based on the time elapsed since the scheduled dose. For delays within a certain timeframe (e.g., less than 12 hours), the guidance often suggests taking the tablet immediately. If the delay is longer than the specified time (e.g., more than 12 hours), instructions generally advise steps to follow for continuing the pack, which may include not taking the missed tablet. Missing a tablet may increase the likelihood of breakthrough bleeding or spotting.

---

Q: Is there a need to take an additional progestogen medication with Cyclo-Progynova N?

The official product information indicates that Cyclo-Progynova N is a combination therapy that already contains both an estrogen and a progestogen (Norgestrel). Based on the product’s formulation, an additional progestogen is generally not required for most users. Any individual requirements for additional medication should be discussed with a healthcare provider.

---

Q: What is the typical pattern for bleeding or spotting while taking this medicine?

According to official sources, a menstrual-like bleed, also known as a withdrawal bleed, usually occurs a few days after taking the last progestogen-containing tablet (the pink tablets). Occasionally, some women may also experience breakthrough bleeding or spotting during the time they are actively taking the tablets.

Storage and Disposal of Cyclo-Progynova N

Official regulatory labeling dictates strict conditions for the storage and disposal of this medicine to maintain its stability and ensure safety.

---

Storage Requirements

• Temperature Control: Do not store the medicine above 30 C.
• Environmental Protection: Keep the tablets in a cool, dry place and protect them from moisture, heat, and direct sunlight.
• Packaging: Keep the tablets in the original calendar pack and blister strip until the time of use.
• Child Safety: The product must be kept out of the sight and reach of children.

---

Disposal Instructions

• Proper Disposal: Return any unused or expired medicine to a pharmacist for disposal.
• Prohibited Disposal: Do not dispose of the tablets in household waste or flush them down the toilet, as instructed by general pharmaceutical waste guidelines.